A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
BACKGROUND: Isoniazid (INH, H) resistance is the most common drug-resistant TB pattern, with treatment success rates lower than those in drug-susceptible TB. The WHO recommends a 6-month regimen of rifampicin (RIF, R), ethambutol (EMB, E), pyrazinamide (PZA, Z), and levofloxacin (Lfx) (6REZLfx) for...
Saved in:
Main Authors: | M.L. Rekart, P. Thit, M. Oluya, S. Moe, T. Hasan, N. Parpieva, K. Safaev, A. Khristusev, T. Zinaida, J. Singh, S. Allamuratova, I. Azamat, C.G. Restrepo, N. Sitali, J. Achar, J.L. Alvaraez, A. Sinha |
---|---|
Format: | Article |
Language: | English |
Published: |
International Union Against Tuberculosis and Lung Disease (The Union)
2024-07-01
|
Series: | IJTLD Open |
Subjects: | |
Online Access: | https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000007/art00002 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan
by: S. Moe, et al.
Published: (2024-09-01) -
Missed rifampicin and isoniazid resistance by commercial molecular assays
by: L Richards, et al.
Published: (2024-07-01) -
Impact of heteroresistance on treatment outcomes of people with drug-resistant TB
by: R. Crowder, et al.
Published: (2024-10-01) -
Progress in programmatic management of drug-resistant TB, WHO Eastern Mediterranean Region, 2018-2023
by: K. Bennani, et al.
Published: (2024-09-01) -
Treating drug-resistant tuberculosis in an era of shorter regimens: Insights from rural South Africa
by: J-D K Lotz, et al.
Published: (2023-11-01)